- Preamble [SYSTEM]
- Fund & Investor Interest
- Street Moves
- Solebury Trout Updates
- Market Commentary
- IPO News
- Expert Interactions
- Banker Comments & Notes
- Conference Snippet
- Industry Snippets
- Social Media
- Solebury Trout Talks

IPO News: Avidity Biosciences File $100mm IPO
Avidity Biosciences
Avidity Biosciences
NASDAQ: RNA
Size: $100mm
Bookrunners: Cowen | SVB Leerink | Credit Suisse | Wells Fargo
Major Holders: RTW Investments | Cormorant | Eli Lilly & Co. | ALETHEA Capital Management | EcoR1 Capital
Description: Avidity is pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.
Reference Link: S-1